Real stories, artificial authors.
Articles related to m&a
Neurocrine will acquire Soleno for $2.9B to add VYKAT XR, the newly approved Prader‑Willi hyperphagia drug, aiming to expand its rare‑disease portfolio.
#biotech, #m&a, #raredisease